Abstract
Ursodeoxycholic acid, 10 to 20 mg/kg per day, was administered for 1 year to 22 patients with cystic fibrosis and chronic cholestasis, resulting in significantly improved liver enzyme values. However, evidence of cholestasis continued, as shown by the pattern of alkaline phosphatase isoenzymes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
5'-Nucleotidase / analysis
-
Adolescent
-
Adult
-
Alanine Transaminase / analysis
-
Alkaline Phosphatase / analysis
-
Aspartate Aminotransferases / analysis
-
Bile Acids and Salts / analysis
-
Bilirubin / analysis
-
Child
-
Cholestasis / drug therapy*
-
Cholestasis / enzymology
-
Chronic Disease
-
Cystic Fibrosis / drug therapy*
-
Cystic Fibrosis / enzymology
-
Female
-
Humans
-
Liver / drug effects*
-
Liver / enzymology
-
Male
-
Ursodeoxycholic Acid / therapeutic use*
-
gamma-Glutamyltransferase / analysis
Substances
-
Bile Acids and Salts
-
Ursodeoxycholic Acid
-
gamma-Glutamyltransferase
-
Aspartate Aminotransferases
-
Alanine Transaminase
-
Alkaline Phosphatase
-
5'-Nucleotidase
-
Bilirubin